Pharmacological Treatment of Acute Stroke

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 24-30

  Wahlgren, Nils Gunnar ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCAVENGER; STREPTOKINASE; TIRILAZAD; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

CONFERENCE PAPER; PRIORITY JOURNAL; STROKE;

EID: 0030952985     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108249     Document Type: Article

References (63)

1. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne M-H, Hennerici M, for the ECASS study group: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study Group (ECASS). JAMA 1995;274:1017-1025.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
3. Sandercock P, for the International Stroke Trial Collaborative Group: The International Stroke Trial. Preliminary results. I. Effects of aspirin and heparin separately and in combination. Cerebrovasc Dis 1996;6(suppl 2):23.
4. Chen ZM, Xie JX, Pcto R, Collins R, Liu LS, on behalf of the CAST Collaborative Group: Chinese Acute Stroke Trial (CAST): Rationale, design and progress. Cerebrovasc Dis 1996; 6(suppl 2):23.
5. Fieschi C, Argentino C, Lenzi GC, Sachetti MC, Toni D, Bozzazo I: Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sei 1989;91:311-321.
6. Wardlaw JM, Warlow CP: Thrombolysis in acute ischaemic stroke; Does it work? Stroke 1992;23:1826-1839.
7. Hommel M, Bogousslavsky J: Thrombolysis in acute cerebral ischaemia. Expert Opin Invest Drugs 1994;3:1011-1020.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of myocardial infarction: ISIS-2. Lancet 1985;1:349—360.
9. Gruppo Italiano per Studio della Sopraviven-zanell'Infano Miocardico: GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336; 65-71.
10. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M, for the Multicentre Acutc Stroke Trial - Europe (MAST-E) Study Group: Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1994;345:57.
11. Hommel M, Cornu C, Boutitie F, Boissel JP, for the Multicentre Acute Stroke Trial - Europe Study Group: Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
12. Multicentre Acute Stroke Trial-Italy (MAST-I) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acutc ischaemic stroke. Lancet 1995;346:1509-1514.
13. Donnan GA, Davis SA, Chambers BR, Gates PC, Hankey GJ, McNeil JJ. Rosen D, Stcwart-Wynne EG, Tuck RG: Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345:578-579.
14. Panncl R, Gurewich V: Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67:1215.
15. Hacke W, Zcumer H, Ferbcrt A, Bruckmann H, Del Zoppo GJ: Intra-arterial thrombolytic therapy improves outcome in patients with acutc vertebrobasilar occlusive disease. Stroke 1988;19:1216-1222.
16. Mori E, Tabuchi M, Yoshida T. Yamadori A: Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802-812.
17. Del Zoppo GJ, Ferbert A, Otis S, Bruckmann H, Hacke W, Zyroff J, Harler LA, Zeumer H: Local intraarterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988;19:307-313.
18. Del Zoppo GJ, Higashida RT, Furlan AJ: The case fora phase III trial of cerebral intraarterial fibrinolysis. AJNR Am J Ncuroradiol 1994; 15: 1217-1222.
19. Reid H, Chan K, Thean P; Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963;1:621 - 626.
20. Poliak VE, Glas-Greenewalt P, Olinger CP, Wadhvva NK, Myre SA: Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325.
21. Olinger CP, Brott TG, Barsan WG: Use of ancrod in acute and progressing ischemic cerebral infarction. Ann Emerg Med 1988; 17: 1208-1209.
22. Sherman DG for the Ancrod Stroke Study Investigators: Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994; 25:1755-1759.
23. Yamaguchi T, Hayakawa T, Kiuchi H, for the Japanese Thrombolysis Study Group: Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cc-rebrovascDis 1993;3:269-272.
24. The ECASS Study Group: European Cooperative Acutc Stroke Study (ECASS): (rt-PA-thrombolysis acutc stroke) Study design and progress report. Eur J Neurol 1995;1:213-219.
25. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Tomer J, Fcinberg W, Mavberg M, Thies W: Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special w riting group of the Stroke Council, American Heart Association. Stroke 1996:27:1711-1718.
26. Kay R, Wong KS, Yu XL. Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong XY, Law CO, Wong A et al: Low-molecular-weight heparin for the treatment of acute ischemic stroke. NEJM 1995;333(24): 1588-1593.
27. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M: BW619C89. a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993;24:1063-1067.
28. Smith SE, Lekicffre D, Sowinski P, Meldrum BS: Ccrcbroprotcctive effect of BW619C89 after focal or global cerebral ischemia in the rat. Neurorcporl 1993;4:1339-1342.
29. Graham SH, Chen J, Lan J, Leach MJ, Simon RP: Neuroprotective effect of a use-dependent blocker of voltage-dependent sodium channels, BW6I9C89, in rat middle cerebral artery occlusion. J Pharmacol ExpThcr 1994;269:854 - 859.
30. Kucharciyk J, Mintorovitch J, Moseley ME, Asgari HS, Scvick RJ, Derugin N, Norman D: Ischemic brain damage: Reduction by sodium-calcium ion channel modulator RS 87476. Radiology 1991;179:221-227.
31. Squire IB, Lees KR, Prvse-Phillips W, Kertesz A, Bamford J: The effects of lifarizine in acute cerebral infarction. A pilot safety study. Cerebrovasc Dis 1996;6:156-160.
32. Fisher M: Potentially effective therapies for acutc ischemic stroke. Eur Neurol 1995; 35:3 - 7.
33. Gotti S, Benavides J, McKcnzic ET, Scatton B: The pharmacotherapy of focal cortical isch-cmia in the mouse brain. Brain Res 1990;522: 290-307.
34. Poignet H, Nowicky JP, Scatton B: Lack of ncuroprotective cffcct of some sigma ligands in a model of focal cerebral ischemia in the mouse. Brain Res 1992,596:320-324.
35. Fisher M: Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995;35:3 - 7.
36. Synthelabo Recherche: Press release. Paris, February'6. 1996.
37. Fisher M, for CNS 1102-003 Investigators: Ccrcstat™ (CNS 1102). a non-competitive NMDA antagonist, in ischcmic stroke patients: Dose-escalating safety study (abstract). Ccrc-brovasc Dis 1994;4:245.
38. Turrini R: A pivotal safety and efficacy of Ce-restat (Aptigancl HCL/CNS 1102) in acutc ischemic stroke patients. Stroke 1996;27:173.
39. Nowak L, Bregestovski P, Aschcr P: Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984;307:462-465.
40. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-mcthvl-£-aspartatc in slices of rat ccrcbral cortex. Br J Pharmacol 1985;84:381-391.
41. Strand T, Wester PO: A double blind randomized pilot trial of magnesium therapy in acute cerebral infarction. 7th Nord Meet Ccrcbro-vascDis, 1993. p 37.
42. Fagg GE. Foster AC: Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience I983;26: 701-719.
43. Green A, Cross AJ, Snapc MF, Dc Souza RJ: The immediate conscqucnces of middle ccre-bral artery occlusion on GABA synthesis in mouse cortex and cerebellum. Neurosci Lett 1992:138:141-144.
44. a receptor complex in rat brain. Br J Pharmacol 1989,98:284-290.
45. Cross AJ, Jones JA, Baldwin HA, Green AR: Neuroprotective activity of chlormcthiazole following transient forebrain ischacmia in the gerbil. Br J Pharmacol 1991:104:406-411.
46. Snapc MF, Baldwin HA, Cross AJ, Green AR: The cITccts of chlormcthiazole and nimodipinc on cortical infarct area after focal cerebral isch-aemia in the rat. Neuroscience I993;53:837-844.
47. Mohr JP, Orgogozo JM, Harrison MJG, Wahlgren NG, Gelmers JH, Mnrtinez-Vila E, Dycka J, Tettenborn D: Meta-analysis of oral nimodipinc trials in acute ischemic stroke. Cc-rebrovasc Dis 1994;4:197-203.
48. Limburg M: Very Early Nimodipinc Use in Stroke - The first 100 patients - Cooperation between GPsand neurologists. Stroke 1996:27; 172.
49. Wahlgren NG, MacMahon D, De Keyser J, Indrcdavik B, Ryman T, for the INWEST Study Group: Intravenous Nimodipine West European Stroke (INWEST) of nimodipinc in the treatment of acute ischaemic stroke. Ccrebrovasc Dis 1994;4:204-210.
50. Scheller D, Kolb J, Szathmary S, Zacharias E, De Ryck M, Van Reempts J, Clinckc B, Tegt-meier F: Extracellular changcs of glutamate in the peri-infarct zone: Effect of lubcluzolc. J Cercb Blood Flow Metab 1995; 15(suppl 1): S379.
51. Lcsagc AS, De Loorc KL, Osikowska-Evers B, Pcetcrs L, Lcyscn JF: Lubcluzole. a novel neu-roprotcctant. inhibits the glutamate-activated NOS pathway. Soc Neurosci Abstr 1994;20: 185.
52. De Ryck M, Keersmackcrs R, Clincke G, Janssen M, Van Reet S: Lubcluzolc. a novel benzothiazole. protects neurologic function after cerebral thrombotic stroke in rats: An apparent stereospecific effect. Soc Neurosci Abstr 1994:20:185.
53. Diener HC, Hacke W, Hennerici M, Rädbcrg J, Hantson L, De Keyser J, for the Lubcluzolc International Study Group: Lubeluzole in acute ischemic stroke. A double-blind placebo-controllcd phase II trial. Stroke 1996;27:76-81.
54. The Lubeluzole Study Group, Janssen Research Foundation: Lubeluzole in ischemic stroke in North America. Stroke 1996;27:172.
55. Herrschaft H: Die Wirksamkeit von Piracetam bei der akuten zerebralen Ischämic des Menschen. Klinisch kontrollierte Doppclblindstu-die Piracctam/10% Dextran 40 versus 10% Dextran 40/Placebo. Med Klin 1988;83:667-677.
56. Heiss WD, Ilsen HW, Wagner R, Pawlik G, Wienhard K: Remote functional depression of glucose metabolism in stroke and its alteration by activating drugs; in Heiss WD, Phelps ME (eds): Positron Emission Tomography of the Brain. Berlin, Springer, 1983. pp 162-168.
57. De Dcyn PP: The Piracetam in Acutc Stroke Study (PASS). Eur J Neurol 1995:2:7.
58. Chan P: Oxygen radicals in focal cerebral isch-cmia. Brain Pathol 1994;4:59-65.
59. Xuc D, Slivka A, Buchan AM: Tirilazad reduces cortical infarction after temporary but not permanent focal cerebral ischemia in rats. Stroke 1992;23:894-899.
60. Haley EC Jr, Kassel NF, Alves WM, Weir BK, Hansen CA: Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1995:82:786-790.
61. Bowes MP, Zivin JA, Rothlcin R: Monoclonal antibody to the ICAM-I adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 1993; 119:215-219.
62. Zhang RL, Chopp M, Zaloga C, Jiang M, Jones M, Miyasaka M, Ward P: Anti-lCAM-antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994;44:1747-1751.
63. Zhang RL, Chopp M, Jiang N, Tang WX. Pros-lak J, Manning AM, Anderson DC: Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle ccrcbral artery occlusion in the Wistar rat. Stroke 1995;26:1438-1443.